Annual
Report
2020
Our teams have shown great resilience in this year 2020 and have demonstrated their determination during this final stretch of the development of an innovative product like Estelle. Getting an approval for a new molecule-based product is exceptional, certainly during this year marked by this unprecedented health crisis.
Leon Van Rompay, Chief Executive Officer
The renewal of our Board of Directors last November has given a dynamic momentum to the development of Mithra, which is about to live a pivotal year in its history. With the support of this new governance, we are determined to bring Mithra closer to its many promises.
Patricia Van Dijck, Chairman of the Board
2020 Highlights
R&D Pipeline
Contraception
First Estetrol product approved in the world
Menopause
Finalization of patient enrolment for the Phase III Program
Covid-19, Perimenopause, Neuroprotection
Coronesta, a new development opportunity in the field of respiratory diseases
Contraception
Successful commercial launches in Europa
Menopause & Osteoporosis
First launch of a tibolone product in North America
Breast & prostate cancer
Injectable implant based on polymer technology
Mithra CDMO
750,000 rings produced in 2020
Brand new injectable production line
Environmental goal: 3256 additional solar panels
292
collaborators
89
new hiring
58
Women
42
Men
Key Figures
Record cash of
139
million
Over
300
million in cash
to be collected
for Estelle
260
million of financial
fundings
including
€ 50 million
Capital commitment
agreement with
LDA Capital Limited
€ 65 million
Capital increase
by means of a
private placement
€ 20 million
Bank loan
€ 125 million
Convertible bonds
